HK1154255A1 - 生物活性肽 - Google Patents

生物活性肽

Info

Publication number
HK1154255A1
HK1154255A1 HK11108062.3A HK11108062A HK1154255A1 HK 1154255 A1 HK1154255 A1 HK 1154255A1 HK 11108062 A HK11108062 A HK 11108062A HK 1154255 A1 HK1154255 A1 HK 1154255A1
Authority
HK
Hong Kong
Prior art keywords
biologically active
active peptides
peptides
biologically
active
Prior art date
Application number
HK11108062.3A
Other languages
English (en)
Inventor
Scheiflinger Friedrich
Dockal Michael
Original Assignee
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH filed Critical Baxalta GmbH
Publication of HK1154255A1 publication Critical patent/HK1154255A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK11108062.3A 2008-04-17 2011-08-03 生物活性肽 HK1154255A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US932608P 2008-04-17 2008-04-17
US11305508P 2008-11-10 2008-11-10
PCT/US2009/040857 WO2009137256A1 (en) 2008-04-17 2009-04-16 Biologically active peptides

Publications (1)

Publication Number Publication Date
HK1154255A1 true HK1154255A1 (zh) 2012-04-13

Family

ID=40887122

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11108062.3A HK1154255A1 (zh) 2008-04-17 2011-08-03 生物活性肽
HK16112064.8A HK1223946A1 (zh) 2008-04-17 2016-10-19 生物活性肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16112064.8A HK1223946A1 (zh) 2008-04-17 2016-10-19 生物活性肽

Country Status (19)

Country Link
US (6) US8563688B2 (zh)
EP (2) EP2279200B1 (zh)
JP (3) JP6038452B2 (zh)
KR (2) KR101606248B1 (zh)
CN (2) CN102007140B (zh)
AR (1) AR071478A1 (zh)
AU (1) AU2009244635B2 (zh)
BR (1) BRPI0911203A2 (zh)
CA (1) CA2721694C (zh)
DK (2) DK2279200T3 (zh)
ES (2) ES2594706T3 (zh)
HK (2) HK1154255A1 (zh)
MX (1) MX2010011397A (zh)
NZ (1) NZ588200A (zh)
PL (1) PL2279200T3 (zh)
PT (1) PT2279200T (zh)
SG (2) SG10201809286XA (zh)
TW (2) TWI573806B (zh)
WO (1) WO2009137256A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
EP2596635B1 (en) 2010-07-19 2020-05-20 Dolby Laboratories Licensing Corporation Enhancement methods for sampled and multiplexed image and video data
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
HUE053223T2 (hu) * 2013-06-11 2021-06-28 Cj Cheiljedang Corp L-izoleucint termelõ mikroorganizmus és eljárás L-izoleucin elõállítására annak alkalmazásával
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US9321812B2 (en) 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
JP6484468B2 (ja) * 2014-06-03 2019-03-13 ＡｖａｎＳｔｒａｔｅ株式会社 ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
KR20190057110A (ko) 2016-09-28 2019-05-27 코바, 인크. 치료적 mots-c 관련 펩타이드
AU2018215092A1 (en) 2017-01-31 2019-08-29 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
EP0693924B2 (en) 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Methods for (in vivo) delivery of biologics and compositions useful therefor
AU711935B2 (en) * 1994-12-30 1999-10-21 Seminis Vegetable Seeds, Inc. Papaya ringspot virus replicase gene
US5532153A (en) * 1995-03-23 1996-07-02 New England Biolabs, Inc. Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US6624289B1 (en) 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU781618C (en) 1999-07-02 2006-03-16 Genentech Inc. FVIIa antagonists
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
WO2001039799A2 (en) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Passive desensitization
JP2004511425A (ja) * 2000-02-08 2004-04-15 ザ　ペン　ステート　リサーチ　ファウンデーション 免疫療法に使用されるインターロイキン１３受容体サブユニットアルファー２
JP4603240B2 (ja) * 2001-05-11 2010-12-22 リサーチ ディベロップメント ファンデーション ＮＦ−κＢ活性化受容体のインヒビターおよびその使用
FR2830865B1 (fr) * 2001-10-17 2004-10-22 Centre Nat Rech Scient Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
US20060204503A1 (en) * 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
EP1968999A2 (en) 2005-12-07 2008-09-17 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
US20090029340A1 (en) 2006-01-04 2009-01-29 Do-Coop Technologies Ltd. Cryoprotective Compositions and Methods of Using Same
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi

Also Published As

Publication number Publication date
JP2011518179A (ja) 2011-06-23
AR071478A1 (es) 2010-06-23
ES2739676T3 (es) 2020-02-03
WO2009137256A1 (en) 2009-11-12
HK1223946A1 (zh) 2017-08-11
US20150038676A1 (en) 2015-02-05
JP6038452B2 (ja) 2016-12-07
BRPI0911203A2 (pt) 2016-07-05
SG10201809286XA (en) 2018-11-29
KR20110005873A (ko) 2011-01-19
AU2009244635A1 (en) 2009-11-12
PT2279200T (pt) 2016-10-12
KR20130112959A (ko) 2013-10-14
JP5977223B2 (ja) 2016-08-24
EP3115370A1 (en) 2017-01-11
CN105524163A (zh) 2016-04-27
AU2009244635B2 (en) 2012-04-19
TW200944226A (en) 2009-11-01
US20170174724A1 (en) 2017-06-22
US8822638B2 (en) 2014-09-02
CA2721694C (en) 2018-11-06
MX2010011397A (es) 2010-11-12
JP2017019797A (ja) 2017-01-26
DK3115370T3 (da) 2019-07-29
US8563688B2 (en) 2013-10-22
US10287319B2 (en) 2019-05-14
ES2594706T3 (es) 2016-12-22
CN102007140B (zh) 2016-02-24
JP2014074052A (ja) 2014-04-24
US9598464B2 (en) 2017-03-21
DK2279200T3 (en) 2016-08-22
EP3115370B1 (en) 2019-06-26
US10822376B2 (en) 2020-11-03
EP2279200B1 (en) 2016-07-13
TWI541020B (zh) 2016-07-11
US20120077749A1 (en) 2012-03-29
PL2279200T3 (pl) 2017-08-31
SG10201608071YA (en) 2016-11-29
US20100022445A1 (en) 2010-01-28
US9206234B2 (en) 2015-12-08
CN102007140A (zh) 2011-04-06
TWI573806B (zh) 2017-03-11
US20190225648A1 (en) 2019-07-25
KR101606248B1 (ko) 2016-03-24
KR101434712B1 (ko) 2014-10-01
NZ588200A (en) 2012-11-30
EP2279200A1 (en) 2011-02-02
TW201443085A (zh) 2014-11-16
CA2721694A1 (en) 2009-11-12
US20160060295A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
HK1223946A1 (zh) 生物活性肽
HK1215182A1 (zh) 包含彈性蛋白樣肽的治療劑
EP2310407A4 (en) BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES
EP2275440A4 (en) GROWTH FACTOR IMITING PEPTIDES AND THEIR USE
HK1164867A1 (en) Biologically active amides
HK1213916A1 (zh) 有生物學活性的、含 -端精氨酸的肽
GB0723712D0 (en) Peptides
GB0920981D0 (en) Peptides
IL199771A0 (en) Active substance combination
GB0816976D0 (en) Protein
EP2123666A4 (en) PEPTIDE
EP2285827A4 (en) PEPTIDES AND ITS USE
HK1152717A1 (zh) 血管生成肽
EP2254901A4 (en) THERAPEUTIC PEPTIDES
GB0703945D0 (en) Peptide
GB0920987D0 (en) Peptides
IL197675A0 (en) Peptides
GB0817978D0 (en) Peptides
GB0818627D0 (en) Protein
GB0812586D0 (en) Chimaeric peptide
GB0815673D0 (en) Peptides
GB0810449D0 (en) Peptides
GB0812093D0 (en) Phylloseptin peptides
GB0814342D0 (en) Functionalised biologically active surfaces
PL384436A1 (pl) Wibroizolator aktywny